Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

Eckardt, Paula; Niu, Jianli; Savage, Angela V.; Griffin, Tara; Sherman, Elizabeth M

doi:10.1177/2325958219835590

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the increasing public awareness of viral hepatitis in the past 2 decades, significant knowledge gaps remain even in the highest risk populations. 2 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt

Ahmed

Shaarawy

Anwar

et al. 2021

J Prim Care Community Health

View full text Add to dashboard Cite

Introduction Interferon-based therapies against the hepatitis C virus had a poor adherence profile. On the other hand, new direct-acting antivirals (DAAs) are orally administered medications, show high efficacy against the hepatitis C virus in addition to a high safety profile. Therefore, adherence to this treatment is expected to improve. Assessment for treatment adherence is mandatory to assess the feasibility of achieving viral hepatitis elimination. Aim The study aims to assess the adherence rate and causes of non-adherence in Egyptian hepatitis C patients who received interferon-free treatment regimens. Methods Retrospective data analysis for 668 hepatitis C patient’s records from August 2014 to October 2019 was done. Assessment of treatment adherence was done by revising the records and phone calls. However, 172 patients were excluded due to the absence of contact data. Rest of patients (n = 496) was categorized into 2 groups: Adherent (n = 432) and non-adherent (n = 64). For whom comparative analysis was done. Results The adherent group (87%) achieved 100 % sustained virological response after 12 weeks (SVR 12). Non-adherence was reported in 12.9% of patients. Low awareness was the main cause of non-adherence (43.75%). BMI was the only significant risk factor for poor adherence ( P = . 04). Other Patient demographics, clinical, and laboratory data didn’t show any significant differences between both groups. Conclusion Interferon-free regimens are tolerable. Raising awareness is mandatory for proper treatment adherence and, subsequently, good clinical outcomes.

show abstract

“…Despite the increasing public awareness of viral hepatitis in the past 2 decades, significant knowledge gaps remain even in the highest risk populations. 2 …”

Section: Introductionmentioning

confidence: 99%

“…Despite the increasing public awareness of viral hepatitis in the past 2 decades, significant knowledge gaps remain even in the highest risk populations. 2 Globally, there are about 71 million patients infected with HCV. Since the introduction of sofosbuvir in 2014, HCV treatment has become more accessible and tolerable.…”

Section: Introductionmentioning

confidence: 99%

Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt

Ahmed

Shaarawy

Anwar

et al. 2021

J Prim Care Community Health

View full text Add to dashboard Cite

show abstract

Predictors of linkage to care for a nontargeted emergency department hepatitis C screening program

Blackwell

Rodgers

Franco³

et al. 2020

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

Evaluation of the impact of a health-system specialty pharmacy patient management program on achieving predefined clinical outcome measures

O’Reilly,

Foushee,

Nolan

et al. 2024

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose Specialty medications often have high costs, pose difficulties with payor approval, and require additional monitoring. Earlier articles have defined various examples of clinical outcome measures (COMs); however, goals and benchmarks have not been well defined, and a gap in the literature exists. This study evaluated the effectiveness of our health-system specialty pharmacy (HSSP) patient management program (PMP) in achieving predefined COM goals. Methods Disease state protocols were developed within the HSSP, and clinical and adherence goals were created for each COM based on primary literature. This retrospective, single-center review examined outcomes and adherence data on patients enrolled in the PMP during 2022. The primary outcome was the number of predefined disease state COM goals met. Secondary outcomes included number of predefined adherence goals met and annual financial impact. Results Of 1,431 patients whose records were reviewed, 1,053 met criteria for inclusion. The primary outcome analysis showed that 84.62% (33 of 39) of the predefined disease state goals were met. Predefined adherence goals were met, with an average proportion of days covered (PDC) for all specialty medications of >90%. The PMP yielded $5,167,043 in direct patient cost savings and $167,260 in cost avoidance. Conclusion The PMP yielded positive results in meeting goals set for the COMs in the disease states managed within the HSSP. COMs will remain a focus for HSSPs to help patients achieve desired clinical outcomes and HSSPs adhere to accreditation standards. More research in this field and standardization of COM goals may benefit the larger HSSP community.

show abstract

Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

Cited by 3 publications

References 25 publications

Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt

Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt

Predictors of linkage to care for a nontargeted emergency department hepatitis C screening program

Evaluation of the impact of a health-system specialty pharmacy patient management program on achieving predefined clinical outcome measures

Contact Info

Product

Resources

About